GCI Health expands with three hires
February 7, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bath, GCI Health, Red Door, starr, woods
Healthcare comms agency GCI Health has grown its London-based team by hiring senior account director Claire Woods, account director Laura …
AstraZeneca battling ‘headwinds’
February 7, 2014Sales and Marketing AstraZeneca, Soriot, farxiga, q4, results, xigduo
AstraZeneca is to shed another 550 jobs as its latest corporate restructure takes shape, bringing to 5,600 the number of …
Six Code breaches for HRA Pharma
February 6, 2014Medical Communications, Sales and Marketing ABPI, HRA Pharma, PMCPA, code, ella one
HRA Pharma has been slammed by the PMCPA after breaching six clauses of the ABPI Code of Practice in its …
Analysts ‘disappointed’ by Sanofi guidance
February 6, 2014Sales and Marketing Aubagio, Plavix, Sanofi, q4, sales
Sanofi has announced a mixed bag for its full year results as analysts have questioned why its forecasts for the …
Gilead to allow cheaper generics of new hep C drug
February 6, 2014Manufacturing and Production, Sales and Marketing Gilead, India, generics, hep C, s&m, sofosbuvir, sovaldi
Gilead has announced the unusual step of allowing its new and highly expensive hepatitis C pill to be sold as …
Nicox makes two appointments
February 6, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NicOx, nguyen, nicolas
French pharma firm Nicox has hired Evelyne Nguyen to be its chief financial officer and Stéphane Nicolas joins its executive …
GSK to make ‘fundamental changes’
February 6, 2014Sales and Marketing China, GSK, Tafinlar, Witty, q4, results
GlaxoSmithKline has pledged to make ‘fundamental changes’ to the manner in which it does business, looking at its interaction with …
Globe faces cancer ‘tidal wave’
February 5, 2014Research and Development, Sales and Marketing Cancer, WHO, globe, world cancer report
The World Health Organisation has warned of a ‘tidal wave’ of cancer cases which it says will sweep across the …
Drug giants team up for Alzheimer’s
February 5, 2014Research and Development, Sales and Marketing Accelerating Medicines Partnership, Alzheimer's, Alzheimer’s, GSK, Merck, National Institutes of Health, Pfizer
The top US medical research agency has brought together a ‘dream team’ of big pharma partners to help battle against …
Laird chief executive takes up key innovation role




February 5, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing david lockwood, laird
David Lockwood OBE has been appointed to an influential business innovation role in the UK as non-executive chair of the …
Three new entries to Cancer Drugs Fund
February 5, 2014Research and Development, Sales and Marketing CDF, Kadcyla, NHS, Tafinlar, UK, xofigo
Three drugs – Roche’s Kadcyla, Bayer’s Xofigo and GlaxoSmithKline’s Tafinlar – have been added to England’s Cancer Drugs Fund (CDF). …
Cancer Research UK turns to gamification with app
February 4, 2014Medical Communications, Sales and Marketing CRUK, Cancer, Gamification, genes in space
Cancer Research UK has launched a new citizen science game aimed at helping its scientists discover new cures for cancer. …
New Ashfield unit to meet pharma’s challenges
February 4, 2014Medical Communications ashfield healthcare
Ashfield healthcare has created a new division to integrate its eight units into one business area offering in an effort …
Pfizer breast cancer drug shows promise
February 4, 2014Research and Development, Sales and Marketing Cancer, Pfizer, breast, femara, letrozole, palbociclib
Pfizer’s experimental breast cancer drug palbociclib has successfully extended progression-free survival in a Phase II trial. The pill was administered …
Biogen Idec’s MS drug gets European approval
February 4, 2014Manufacturing and Production, Sales and Marketing Aubagio, Biogen IDEC, EU, MS, gilenya, tecdifera
Biogen Idec’s oral multiple sclerosis drug Tecfidera has won approval in Europe as a first-line treatment for people with relapsing-remitting …
AstraZeneca ‘simplifies decision-making’
February 4, 2014Sales and Marketing AstraZeneca, BMS, Byetta, Forxiga, Onglyza, diabetes
AstraZeneca has completed its $4.3 billion acquisition of Bristol-Myers Squibb’s diabetes business, giving the company control over several big-name brands …
Sir Michael Parkinson criticises NICE
February 4, 2014Medical Communications, Sales and Marketing Astellas, NHS, NICE, Xtandi, parkinson, prostate
TV host Sir Michael Parkinson has told NICE that it must lift the restrictions imposed on Astellas’ new prostate cancer …
Sartorius hires laboratory manager
February 4, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Michael Melingo, satorius
Lab and technology firm Sartorius has appointed Michael Melingo to be its laboratory manager. Melingo is to succeed Dominique Baly …
Roche: NICE guidance ‘perverse’
February 4, 2014Sales and Marketing NHS, NICE, NSCLC, Roche, Tarceva
Roche has poured scorn on NICE’s ‘perverse’ recommendation that its EGFR-TK inhibitor Tarceva should no longer be given to NHS …
J&J reveals more on transparency policy
February 3, 2014Medical Communications, Research and Development, Sales and Marketing Goldacre, J&J, JJ, alltrials, johnson, transparency, yoda
Johnson & Johnson’s pharma subsidiary Janssen has given Pharmafile more details on its new transparency policy, which will see both …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
